IP Library Granted Patent US 11,591,588
Granted Patent B2
US 11,591,588 · App. 17/091,479 · Granted Feb 28, 2023

Penicillin-G acylases

Inventors: Oscar Alvizo (Fremont, CA); David Elgart (San Mateo, CA); Robert Kevin Orr (Cranford, NJ); James Nicholas Riggins (San Francisco, CA); Anna Fryszkowska (New York, NY); Katrina W. Lexa (Santa Rosa, CA); Xiang Yi (San Carlos, CA); Da Duan (Newark, CA); Courtney Dianne Moffett (San Francisco, CA); Nikki Dellas (San Carlos, CA); Vesna Mitchell (Santa Clara, CA)
Assignee: Codexis, Inc.
C12N9/84C07K14/62C12P21/02C12Y305/01011C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,591,588
App. No.
17/091,479
Granted
Feb 28, 2023
Kind
B2
Abstract

The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Claims (10)

1. An engineered penicillin G acylase capable of acylating insulin, wherein the polypeptide sequence of said penicillin G acylase is at least 85% identical to SEQ ID NO: 100, and wherein said penicillin G acylase comprises a substitution at position 436 as compared to SEQ ID NO: 100.

2. The engineered penicillin G acylase of claim 1 , wherein said engineered penicillin G acylase comprises a polypeptide sequence selected from SEQ ID NOS:100, 110 and 142.

3. A method for producing acylated insulin, comprising: providing the engineered penicillin G acylase of claim 1 and insulin; exposing said engineered penicillin G acylase and said insulin under conditions such that said engineered penicillin G acylase acylates said insulin, thereby producing acylated insulin.

4. The method of claim 3 , wherein said acylation is conducted in the presence of methyl phenylacetate.

5. The method of claim 3 , wherein said acylation occurs at any of positions A1, B1, and/or B29 of said insulin.

6. The method of claim 4 , wherein said acylation occurs at any of positions A1, B1, and/or B29 of said insulin.

7. The method of claim 3 , wherein said acylation occurs at position A1 of said insulin.

8. The method of claim 3 , wherein said acylation occurs at position B1 of said insulin.

9. The method of claim 3 , wherein said acylation occurs at position B29 of said insulin.

10. The method of claim 3 , wherein said acylation occurs at positions A1, B1, and B29 of said insulin.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (5)
Continuation 16927129 · Jul 13, 2020
Division 15861849 · Jan 4, 2018
Provisional Application 62442810 · Jan 5, 2017
Provisional Application 62472055 · Mar 16, 2017
Related Publication 20210054357A1 · Feb 25, 2021